Drug Classification · Questions 1–6
Identify the pharmacological class or categorical label for each drug. Vocabulary preparation is sufficient to answer every question in this section.
Question 1
Which of the following best describes the pharmacological classification of ethosuximide?
Correct Answer
B — T-type calcium channel blocker
Rationale
Ethosuximide is classified as a T-type calcium channel blocker. It selectively blocks T-type calcium channels in thalamic relay neurons, which interrupts the rhythmic thalamocortical firing that generates absence seizures. Sodium channel blockers include phenytoin, carbamazepine, and lamotrigine. Gamma-aminobutyric acid type A receptor enhancers include the benzodiazepines and phenobarbital. Synaptic vesicle protein 2A modulators include levetiracetam, which works through a mechanism unrelated to ion channels.
Question 2
Which of the following anti-seizure drugs is classified as a broad-spectrum agent with proven efficacy against both focal and generalized seizure types?
Correct Answer
D — Valproate
Rationale
Valproate is a broad-spectrum anti-seizure drug effective against focal seizures, generalized tonic-clonic seizures, absence seizures, and myoclonic seizures. Ethosuximide is narrow-spectrum — it is effective only for absence seizures and has no efficacy against tonic-clonic or myoclonic seizures. Carbamazepine is narrow-spectrum — it is effective for focal and tonic-clonic seizures but can worsen absence and myoclonic seizures. Phenytoin is similarly narrow-spectrum, effective for focal and tonic-clonic seizures but contraindicated in absence epilepsy.
Question 3
Which of the following anti-seizure drugs is classified as a synaptic vesicle protein 2A modulator?
Correct Answer
A — Levetiracetam
Rationale
Levetiracetam binds synaptic vesicle protein 2A, a presynaptic protein involved in neurotransmitter release, and is classified by this unique mechanism. No other drug in routine clinical use shares this class label. Lamotrigine is a sodium channel blocker with some additional actions. Topiramate works through multiple mechanisms including sodium channel blockade, gamma-aminobutyric acid type A enhancement, and glutamate inhibition. Phenobarbital is a barbiturate that enhances gamma-aminobutyric acid type A receptor activity.
Question 4
Phenobarbital belongs to which of the following drug classes?
Correct Answer
C — Barbiturate
Rationale
Phenobarbital is a barbiturate. Both barbiturates and benzodiazepines enhance gamma-aminobutyric acid type A receptor activity, but they are distinct drug classes with different binding sites, different effects on chloride channel behavior, and different clinical profiles. Benzodiazepines include diazepam, lorazepam, and clonazepam. Hydantoins include phenytoin and fosphenytoin. Succinimides include ethosuximide, which is the first-line agent for childhood absence epilepsy.
Question 5
Despite its name, gabapentin does not act as a gamma-aminobutyric acid receptor agonist. Which of the following correctly identifies the pharmacological class of gabapentin?
Correct Answer
A — Alpha-2-delta subunit ligand
Rationale
Gabapentin is classified as an alpha-2-delta subunit ligand. It binds the alpha-2-delta subunit of voltage-gated calcium channels and is not a gamma-aminobutyric acid receptor agonist — the name is structurally derived from gamma-aminobutyric acid but does not reflect the drug's mechanism of action. This distinction is among the most frequently tested facts about gabapentin. Sodium channel blockers include phenytoin, carbamazepine, and lamotrigine. Synaptic vesicle protein 2A modulators include levetiracetam.
Question 6
Which of the following anti-seizure drugs is classified as a narrow-spectrum agent that is effective for focal and tonic-clonic seizures but is contraindicated in absence epilepsy?
Correct Answer
C — Carbamazepine
Rationale
Carbamazepine is a narrow-spectrum anti-seizure drug. It is effective for focal seizures and generalized tonic-clonic seizures but can worsen absence seizures and myoclonic seizures, making it contraindicated in patients with these seizure types. Lamotrigine is broad-spectrum — it is effective against absence seizures in addition to focal and tonic-clonic seizures. Levetiracetam is also broad-spectrum with efficacy across multiple seizure types. Valproate is broad-spectrum and is, in fact, a preferred drug for absence epilepsy when other seizure types are also present.
Core Pharmacology · Questions 7–14
Apply your understanding of drug mechanisms, pharmacokinetics, and adverse effects. Each question requires one reasoning step.
Question 7
A 12-year-old girl with childhood absence epilepsy is started on carbamazepine by a covering physician who misread the seizure type in the chart. Over the following two weeks, her parents report that her staring episodes have become more frequent. Which of the following best explains this outcome?
Correct Answer
B — Carbamazepine is a narrow-spectrum agent that can worsen absence seizures
Rationale
Carbamazepine is effective for focal and tonic-clonic seizures but is a narrow-spectrum drug that can worsen absence seizures and myoclonic seizures. Prescribing it to a patient with absence epilepsy can increase seizure frequency — exactly the outcome described here. This is a patient safety issue that depends on correct seizure classification before initiating therapy. Phenytoin and gabapentin share this property and are similarly contraindicated in absence epilepsy. Option C describes carbamazepine autoinduction, which is a real pharmacokinetic property but causes subtherapeutic levels rather than seizure worsening of a different seizure type. Options A and D describe mechanisms that carbamazepine does not produce.
Question 8
A 7-year-old boy is brought to the pediatrician after his teacher reports that he has frequent episodes of staring blankly for several seconds, after which he immediately resumes normal activity without confusion. An electroencephalogram shows three-per-second spike-and-wave discharges. No other seizure types are identified. Which of the following is the most appropriate first-line pharmacotherapy for this patient?
Correct Answer
D — Ethosuximide
Rationale
This patient has childhood absence epilepsy — frequent brief staring episodes with immediate return to full consciousness, no postictal confusion, and the characteristic three-per-second spike-and-wave pattern on electroencephalogram. When absence seizures occur without other seizure types, ethosuximide is the drug of choice. Valproate is reserved for patients whose absence epilepsy coexists with tonic-clonic or myoclonic seizures, because ethosuximide has no efficacy against those types. Carbamazepine and phenytoin are contraindicated in absence epilepsy — both are narrow-spectrum agents that can worsen absence seizures. Levetiracetam is a broad-spectrum agent used for other seizure types but is not the established first-line choice for pure childhood absence epilepsy.
Question 9
A 16-year-old boy reports brief jerking movements of his arms most mornings shortly after waking, twice accompanied by a generalized tonic-clonic seizure. His symptoms are worse after late nights and alcohol use at a recent party. Which of the following drugs is most appropriate as first-line therapy for this patient's epilepsy syndrome?
Correct Answer
A — Valproate
Rationale
This patient has juvenile myoclonic epilepsy — the combination of myoclonic jerks occurring in the morning after waking, generalized tonic-clonic seizures, and provocation by sleep deprivation and alcohol is characteristic. Valproate is first-line because it has proven efficacy against all three seizure types that occur in juvenile myoclonic epilepsy: myoclonic, tonic-clonic, and absence. Ethosuximide is effective only for absence seizures and has no efficacy against myoclonic or tonic-clonic seizures. Carbamazepine and phenytoin are narrow-spectrum agents that can worsen myoclonic seizures and are avoided in this syndrome.
Question 10
A 34-year-old woman has recurrent seizures that begin with a rising sensation in her abdomen, followed by impaired awareness and repetitive lip-smacking movements lasting about 90 seconds. She has no history of other seizure types. Imaging shows right mesial temporal sclerosis. Which of the following drug classes is most appropriate as initial pharmacotherapy for this patient?
Correct Answer
C — Sodium channel blockers
Rationale
This patient has temporal lobe epilepsy — focal seizures with an aura (epigastric rising sensation), impaired awareness, and automatisms (lip smacking), arising from a focal structural lesion. Focal epilepsy is treated with drugs appropriate for focal-onset seizures, and sodium channel blockers are the traditional first-line class for this indication. Carbamazepine, lamotrigine, and oxcarbazepine are all sodium channel blockers used for focal epilepsy, with carbamazepine historically the most established choice. T-type calcium channel blockers such as ethosuximide are specific to absence seizures and have no role in focal epilepsy. Alpha-2-delta subunit ligands such as gabapentin are used as adjunctive agents for focal seizures but are not established first-line monotherapy.
Question 11
A 19-year-old woman has a history of both absence seizures and generalized tonic-clonic seizures. Her neurologist explains that the drug selected must be effective against both seizure types simultaneously. Which of the following properties is most important in selecting an appropriate anti-seizure drug for this patient?
Correct Answer
B — Broad-spectrum coverage with efficacy against multiple seizure types
Rationale
When a patient has mixed seizure types, a broad-spectrum agent is required — one with efficacy across both seizure types present. Narrow-spectrum agents such as ethosuximide cover only absence seizures and would leave tonic-clonic seizures untreated. Worse, narrow-spectrum agents such as carbamazepine and phenytoin are effective for tonic-clonic seizures but can worsen absence seizures. Valproate is the prototypical broad-spectrum agent for this clinical situation: it is effective against absence, tonic-clonic, and myoclonic seizures. Selective T-type calcium channel blockade describes ethosuximide's mechanism, which is narrow-spectrum. Synaptic vesicle protein 2A modulation describes levetiracetam, which is broad-spectrum but is not the most established first-line choice for absence combined with tonic-clonic seizures.
Question 12
Anti-seizure drugs reduce seizure frequency by correcting the imbalance between neuronal excitation and inhibition. Which of the following correctly pairs a drug with its primary mechanism category?
Correct Answer
D — Phenytoin — sodium channel blockade
Rationale
Phenytoin works by blocking voltage-gated sodium channels, reducing the ability of neurons to fire repetitively at the high frequencies that sustain seizures. Sodium channel blockade is the correct mechanism category for phenytoin. Ethosuximide works by blocking T-type calcium channels in thalamic relay neurons — its primary mechanism is calcium channel blockade, not gamma-aminobutyric acid enhancement. Phenobarbital works by enhancing gamma-aminobutyric acid type A receptor activity — it increases the duration of chloride channel opening, placing it in the gamma-aminobutyric acid enhancement category, not sodium channel blockade. Carbamazepine is also a sodium channel blocker, not a calcium channel blocker.
Question 13
A 28-year-old man has his first unprovoked seizure. After evaluation, his neurologist prescribes an anti-seizure drug to reduce the risk of recurrence. The patient asks whether the drug will cure his condition. Which of the following best describes the pharmacological role of anti-seizure drugs in epilepsy?
Correct Answer
A — They suppress seizure activity but do not alter the underlying neurological predisposition
Rationale
Anti-seizure drugs prevent recurrent seizures in epilepsy but do not cure the underlying condition. They work by correcting the excitation-inhibition imbalance that lowers the seizure threshold — but this effect is present only while the drug is active. The neurological predisposition to seizures persists. This distinction matters clinically: patients who stop medication abruptly risk withdrawal seizures and recurrence. Options B, C, and D all describe curative or disease-modifying actions that current anti-seizure drugs do not produce.
Question 14
A pharmacology student reads that gabapentin was originally synthesized as a gamma-aminobutyric acid analog and concludes that it must work by directly activating gamma-aminobutyric acid receptors. Which of the following correctly identifies the error in this reasoning?
Correct Answer
C — Gabapentin binds the alpha-2-delta subunit of voltage-gated calcium channels and does not act at gamma-aminobutyric acid receptors
Rationale
Despite its name, gabapentin is not a gamma-aminobutyric acid receptor agonist and does not act directly at gamma-aminobutyric acid type A or type B receptors. Its name reflects its structural derivation from gamma-aminobutyric acid, not its mechanism. Gabapentin binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing calcium influx and neurotransmitter release at synapses. Option A assigns it to gamma-aminobutyric acid type B receptors — ethosuximide targets T-type calcium channels, not gamma-aminobutyric acid receptors. Option B describes a synthesis effect that gabapentin does not produce. Option D describes valproate's mechanism of gamma-aminobutyric acid transaminase inhibition, which increases synaptic gamma-aminobutyric acid but is not gabapentin's mechanism.
Clinical Correlations · Questions 15–18
Apply pharmacological knowledge to clinical scenarios. Each vignette presents a patient situation; the question tests mechanism of action or drug selection.
Question 15
A 7-year-old boy has episodes in which he suddenly stops speaking mid-sentence, stares blankly for 10 seconds, then immediately continues the conversation without any confusion. His teacher reports up to 30 such episodes per day. A second child in the same class has episodes of staring and unresponsiveness lasting 90 seconds, after which she appears confused and tired. Which of the following drugs is appropriate for the first child but contraindicated in the second child because it can worsen her seizure type?
Correct Answer
B — Ethosuximide
Rationale
The first child has absence seizures — brief staring spells with abrupt onset and offset and no postictal confusion, occurring many times per day. The second child has focal seizures with impaired awareness — longer duration, followed by postictal confusion and fatigue. Ethosuximide is the drug of choice for childhood absence epilepsy, but it has no efficacy against focal seizures and would leave the second child's seizures untreated. The question asks which drug is appropriate for the first child but contraindicated in the second — ethosuximide fits because it covers absence but not focal seizures. Valproate and lamotrigine are broad-spectrum agents effective for both seizure types. Levetiracetam is also broad-spectrum and would not be contraindicated for the second child.
Question 16
An 8-year-old girl has been diagnosed with childhood absence epilepsy and is well controlled on ethosuximide. At a follow-up visit, her mother reports that the girl has now had two generalized tonic-clonic seizures over the past month. Her neurologist decides to change her medication. Which of the following best explains why ethosuximide alone is no longer appropriate for this patient?
Correct Answer
D — Ethosuximide has no efficacy against tonic-clonic seizures, so a broad-spectrum agent is now required
Rationale
Ethosuximide is a narrow-spectrum drug effective only for absence seizures. It has no efficacy against tonic-clonic or myoclonic seizures. When a patient with childhood absence epilepsy develops tonic-clonic seizures, ethosuximide alone is insufficient — a broad-spectrum agent such as valproate is required because it covers both absence and tonic-clonic seizure types. This is the defining reason ethosuximide is restricted to patients with pure absence epilepsy: the moment another seizure type appears, the drug cannot address it. Options A, B, and C describe pharmacological properties that ethosuximide does not possess.
Question 17
A 22-year-old man presents after a first-ever seizure. Witnesses describe generalized convulsive activity, but the patient recalls a brief aura beforehand, suggesting possible focal onset. Electroencephalogram findings are inconclusive regarding whether the seizures are focal or generalized in origin. The neurologist decides to initiate pharmacotherapy before the seizure type is definitively classified. Which of the following properties is most important in selecting an anti-seizure drug for this patient at this time?
Correct Answer
A — Broad-spectrum coverage, to avoid worsening a seizure type that has not yet been excluded
Rationale
When the seizure type is uncertain, a broad-spectrum agent is preferred because narrow-spectrum drugs can worsen certain seizure types. If this patient has absence or myoclonic seizures that have not yet been identified, starting a narrow-spectrum sodium channel blocker such as carbamazepine or phenytoin could increase seizure frequency. Broad-spectrum agents such as valproate, lamotrigine, and levetiracetam are effective across multiple seizure types and do not carry the risk of worsening absence or myoclonic seizures. Option C describes selective T-type calcium channel blockade — the mechanism of ethosuximide, which is narrow-spectrum and effective only for absence seizures, not broad-spectrum coverage. Option D overstates levetiracetam's profile — while it has a favorable spectrum, it is not the only mechanism without seizure-type contraindications.
Question 18
A neurologist is selecting pharmacotherapy for a 25-year-old man with focal seizures with impaired awareness arising from a left temporal focus. The neurologist chooses a narrow-spectrum sodium channel blocker that is a traditional first-line agent for focal-onset seizures. The patient also has occasional absence seizures that were not mentioned during the initial visit. Which of the following is the most likely consequence of the selected drug on the patient's absence seizures?
Correct Answer
C — The absence seizures will worsen because the drug is a narrow-spectrum agent contraindicated in absence epilepsy
Rationale
The drug described — a narrow-spectrum sodium channel blocker that is first-line for focal-onset seizures — is carbamazepine. While carbamazepine is effective for focal and tonic-clonic seizures, it can worsen absence seizures and is contraindicated in patients with absence epilepsy. This is why accurate and complete seizure classification before initiating therapy is a patient safety requirement. A broad-spectrum agent such as lamotrigine or valproate would be the appropriate choice for a patient with both focal and absence seizures. Option D attributes the worsening to gamma-aminobutyric acid transaminase inhibition — this is valproate's mechanism, not carbamazepine's, and valproate does not worsen absence seizures.